A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis.

Details

Language :

English

ISSN :

21522650

Volume :

19

Database :

Complementary Index

Journal :

Clinical Lymphoma, Myeloma & Leukemia

Publication Type :

Academic Journal

Accession number :

139238099

Full Text :

https://doi.org/10.1016/j.clml.2019.09.543